THE ADAPTED PROJECT

The ADAPTED (Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development)  project is a major new initiative to investigate an area of Alzheimer's Disease (AD) research which has previously received little attention. The project aims to improve understanding of the function of the APOE gene. APOE is well known as a risk factor for developing the disease but precisely how this gene contributes to the risk of developing AD is not known.

ADAPTED brings together the expertise of researchers in universities, research institutes and biotech and pharmaceutical companies from across Europe and the USA. Using the expertise of the ADAPTED partners in a range of cutting-edge biological analysis methods the project will attempt to really unravel the complexities of the APOE gene as well as providing the research community with a new generation of human cell –based tools to mimic and investigate the causes and progression of the disease.

​

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 115975. This Joint Undertaking received support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. The project runs from 1st October 2016 to 30th September 2019 and has an estimated budget of €6.8M